Axcella to Present Data on AXA1125 at Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium
Axcella Health, a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Svetlana Marukian, Ph.D., Senior Director, Discovery, will present new data from Axcella’s AXA1125 liver program at the Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium, taking place January 20-24, 2019 in Sante Fe, NM. New data in primary human single and multicellular systems show that AXA1125, a novel AXATM candidate, affects metabolic, inflammatory and fibrotic pathways. These results demonstrate high fidelity to observations in T2DM subjects with NAFLD recently presented at the 2018 American Association for the Study of Liver Diseases (AASLD) Liver Meeting®.
Additional details of the presentation are as follows:
Title: Unique Composition of Endogenous Modulators Impact Metabolic, Inflammation, and Fibrotic Markers in NAFLD/NASH Model Systems
Presenter: Svetlana Marukian, Ph.D., Senior Director of Discovery
Session: Innate Immune and Inflammatory Signaling
Location: Eldorado Grand Ballroom, Eldorado Hotel
Date/Time: Tuesday, January 22, 2019 at 5:00 PM MT
About Endogenous Metabolic Modulators
Endogenous metabolic modulators (EMMs), which include amino acids, regulate fundamental pathways in health and disease. Compositions leveraging EMMs hold significant promise, with several advantages over traditional drugs and food/dietary supplement products, including their ability to simultaneously impact multiple biological pathways and history of safe use.
About Non-IND Clinical Studies
Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND. Axcella has not determined the development path for AXA1125.
About Axcella™ Health
Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and development of traditional drug and consumer health candidates from concept to clinical stages, by leveraging our deep understanding of human biology. Our novel approach rapidly gains unprecedented information in a capital efficient manner. Our platform has already produced a rich pipeline of product candidates in programs targeting liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering. www.axcellahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181221005069/en/